ACET
Adicet Bio Inc

3,736
Mkt Cap
$69.19M
Volume
146,303.00
52W High
$17.44
52W Low
$6.41
PE Ratio
-0.36
ACET Fundamentals
Price
$7.21
Prev Close
$7.04
Open
$6.98
50D MA
$7.67
Beta
1.03
Avg. Volume
194,134.69
EPS (Annual)
-$16.95
P/B
0.34
Rev/Employee
$0.00
$85.77
Loading...
Loading...
News
all
press releases
Guggenheim Issues Pessimistic Forecast for Adicet Bio (NASDAQ:ACET) Stock Price
Guggenheim cut their price target on Adicet Bio from $128.00 to $100.00 and set a "buy" rating for the company in a report on Friday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Adicet Bio (NASDAQ:ACET) Releases Earnings Results, Beats Expectations By $0.29 EPS
Adicet Bio (NASDAQ:ACET - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($2.94) earnings per share for the quarter, beating the consensus estimate of...
MarketBeat·3d ago
News Placeholder
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial...
Business Wire·3d ago
News Placeholder
Adicet Bio (NASDAQ:ACET) Stock Passes Below 200 Day Moving Average - Here's What Happened
Adicet Bio (NASDAQ:ACET) Shares Pass Below Two Hundred Day Moving Average - Should You Sell...
MarketBeat·5d ago
News Placeholder
Adicet Bio, Inc. (NASDAQ:ACET) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the company, MarketBeat...
MarketBeat·13d ago
News Placeholder
Adicet Bio (ACET) Projected to Post Quarterly Earnings on Thursday
Adicet Bio (NASDAQ:ACET) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...
MarketBeat·17d ago
News Placeholder
Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from Analysts
Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are currently covering the company, Marketbeat Ratings reports...
MarketBeat·1mo ago
News Placeholder
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
Business Wire·1mo ago
News Placeholder
HC Wainwright Reduces Earnings Estimates for Adicet Bio
Adicet Bio, Inc. (NASDAQ:ACET - Free Report) - Equities researchers at HC Wainwright decreased their FY2025 earnings per share estimates for Adicet Bio in a report released on Wednesday, January...
MarketBeat·2mo ago
News Placeholder
Adicet Bio (NASDAQ:ACET) Shares Pass Below 200-Day Moving Average - What's Next?
Adicet Bio (NASDAQ:ACET) Stock Crosses Below 200-Day Moving Average - What's Next...
MarketBeat·2mo ago
<
1
2
...
>

Latest ACET News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.